Medifron DBT Co. Ltd (065650) - Total Liabilities

Latest as of September 2025: ₩86.61 Billion KRW ≈ $58.70 Million USD

Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has total liabilities worth ₩86.61 Billion KRW (≈ $58.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Medifron DBT Co. Ltd annual equity growth to track the company's year-over-year net asset growth rate.

Medifron DBT Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Medifron DBT Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 065650 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Medifron DBT Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Medifron DBT Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
SBC Corp Bhd KLSE:5207	Malaysia	RM156.58 Million
HM Inwest S.A. WAR:HMI	Poland	zł157.19 Million
Kiang Huat Sea Gull Trading Frozen Food Public Company Limited BK:CHOTI	Thailand	฿1.71 Billion
Linius Technologies Ltd AU:LNU	Australia	AU$3.90 Million
Zenta Group Company Limited Ordinary Shares NASDAQ:ZGM	USA	$429.97K
Cairn Homes PLC LSE:CRN	UK	GBX522.49 Million
Viji Finance Limited NSE:VIJIFIN	India	Rs134.80 Million
Aegis Brands Inc TO:AEG	Canada	CA$31.73 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Medifron DBT Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 065650 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.01	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medifron DBT Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medifron DBT Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Medifron DBT Co. Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩42.92 Billion ≈ $29.08 Million	+127.15%
2023-12-31	₩18.89 Billion ≈ $12.80 Million	-23.39%
2022-12-31	₩24.66 Billion ≈ $16.71 Million	+262.30%
2021-12-31	₩6.81 Billion ≈ $4.61 Million	-64.84%
2020-12-31	₩19.36 Billion ≈ $13.12 Million	+994.02%
2019-12-31	₩1.77 Billion ≈ $1.20 Million	-25.45%
2018-12-31	₩2.37 Billion ≈ $1.61 Million	+58.92%
2017-12-31	₩1.49 Billion ≈ $1.01 Million	-31.47%
2016-12-31	₩2.18 Billion ≈ $1.48 Million	-69.04%
2015-12-31	₩7.04 Billion ≈ $4.77 Million	+356.92%
2014-12-31	₩1.54 Billion ≈ $1.04 Million	--

About Medifron DBT Co. Ltd

KQ:065650 Korea Biotechnology

Market Cap

$16.05 Million

₩23.69 Billion KRW

Market Cap Rank

#25752 Global

#1909 in Korea

Share Price

₩1780.00

Change (1 day)

+10.90%

52-Week Range

₩1476.00 - ₩4575.00

All Time High

₩8800.00